To investigate therapeutic efficacy of a combined inhibition of FLT3, PI3K and GLI on growth of AML cells, the FLT3-mutated AML cell lines MV4-11 and MOLM-13, as well as FLT3 wildtype cell line OCI-AML5 were treated with different concentrations of the FLT3 inhibitor sunitinib, the PI3K inhibitor PF-04691502 and the GLI inhibitor GANT61 either alone or in combination of two or all three agents. The gene discussed is FLT3; the disease is acute myeloid leukemia.